Resumo
Definição
História e exame físico
Principais fatores de diagnóstico
- presença de fatores de risco
- ansiedade antecipatória e preocupação
- taquicardia
- hiperventilação
- sudorese
- rubor
- tensão muscular
Outros fatores de diagnóstico
- processamento pós-evento
- vieses de atenção
- deficits de habilidades sociais
- choro, acessos de raiva ou "paralisia"
Fatores de risco
- comorbidade psiquiátrica (por exemplo, transtornos de ansiedade, humor e abuso de substâncias)
- genética
- fatores de temperamento
- estilo de criação
- transtorno psicológico
- estressores da vida
- fatores ambientais
Exames diagnósticos
Exames a serem considerados
- glicose sanguínea
- hormônio estimulante da tireoide sérico
- análise toxicológica (urina e sangue)
Algoritmo de tratamento
Colaboradores
Autores

Associate Professor
Department of Psychiatry and Psychology
Mayo Clinic
Rochester
MN
Divulgações
CNS declares that he has no competing interests.

Assistant Professor
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle
WA
Divulgações
JPV declares that he has no competing interests.

Associate Professor
Department of Psychological Sciences
Vanderbilt University
Nashville
TN
Divulgações
BOO declares that he has no competing interests.

Director
Anxiety and Stress Reduction Center of Seattle
University of Washington
Seattle
WA
Divulgações
SSW declares that she has no competing interests.
Colegas revisores
Emeritus Professor
Medical Director
Anxiety Treatment and Research Centre
McMaster University and St Joseph’s Hospital
Hamilton
Canada
Divulgações
RPS declares that he has no competing interests.
Professor
Department of Psychology
University of Arkansas
Fayetteville
AR
Divulgações
JML declares that he has no competing interests.
Associate Professor
Institute of Living
Yale University
New Haven
CT
Divulgações
DFT declares that he has no competing interests.
Professor of Psychiatry
University of Southampton
Southampton
UK
Divulgações
DB has acted as a consultant for and held research grants from Cephalon, Eli Lilly, GSK, Lundbeck, Organon, Pfizer, Pharmacia, Roche, and Wyeth and has also acted as a consultant to Asahi, AstraZeneca, Grunenthal, Pierre Fabre, Servier, Sumitomo, and Wyeth. He has accepted paid speaking engagements in industry-supported satellite symposia and is co-author of the BAP evidence-based guidelines on the treatment of anxiety disorders. He is also a Medical Patron of Anxiety UK.
O uso deste conteúdo está sujeito aos nossos avisos legais